MX337206B - Variantes de factor neurotrófico derivado de celulas gliales humanas. - Google Patents

Variantes de factor neurotrófico derivado de celulas gliales humanas.

Info

Publication number
MX337206B
MX337206B MX2013011919A MX2013011919A MX337206B MX 337206 B MX337206 B MX 337206B MX 2013011919 A MX2013011919 A MX 2013011919A MX 2013011919 A MX2013011919 A MX 2013011919A MX 337206 B MX337206 B MX 337206B
Authority
MX
Mexico
Prior art keywords
variants
human gdnf
gdnf
human
methods
Prior art date
Application number
MX2013011919A
Other languages
English (en)
Other versions
MX2013011919A (es
Inventor
Donmienne Doen Mun Leung
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O Bryan
Rosamund Carol Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2013011919A publication Critical patent/MX2013011919A/es
Publication of MX337206B publication Critical patent/MX337206B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente invención se refiere a una nueva variante de GDNF truncada de dominio GDNF humano maduro que carece de los primeros 31 aminoácidos en el N-término ("GDNF truncado de ?31-N-término"), con ciertas sustituciones de aminoácidos introducidas para proporcionar variantes de GDNF, adecuadamente potentes, estables, que ofrecen propiedades de bio-distribución deseable y un perfil de inmunogenicidad farmacéuticamente aceptable. La presente invención proporciona ciertas variantes de GDNF humano que imparten una o más ventajas sobre el GDNF de tipo nativo humano maduro que incluye variantes que tienen estabilidad farmacéutica mejorada, así como también bio-distribución mejorada, enlace de heparina reducido, desamidación reducida susceptibilidad reducida para formación de succinimida, y potencial de inmunogenicidad reducida comparado con el GDNF de tipo nativo humano. Ciertas nuevas variantes del GDNF pueden ser una opción de nuevo tratamiento útil para pacientes con enfermedad de Parkinson.
MX2013011919A 2011-04-11 2012-04-03 Variantes de factor neurotrófico derivado de celulas gliales humanas. MX337206B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (2)

Publication Number Publication Date
MX2013011919A MX2013011919A (es) 2014-03-27
MX337206B true MX337206B (es) 2016-02-17

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011919A MX337206B (es) 2011-04-11 2012-04-03 Variantes de factor neurotrófico derivado de celulas gliales humanas.

Country Status (28)

Country Link
US (1) US9243046B2 (es)
EP (1) EP2696889B1 (es)
JP (1) JP6093345B2 (es)
KR (1) KR101554799B1 (es)
CN (1) CN103635201B (es)
AU (1) AU2012243178B2 (es)
BR (1) BR112013026004B1 (es)
CA (1) CA2833158C (es)
CY (1) CY1119750T1 (es)
DK (1) DK2696889T3 (es)
EA (1) EA025129B1 (es)
ES (1) ES2656020T3 (es)
HR (1) HRP20171993T1 (es)
HU (1) HUE036239T2 (es)
IL (1) IL228102A (es)
LT (1) LT2696889T (es)
ME (1) ME02849B (es)
MX (1) MX337206B (es)
NO (1) NO2696889T3 (es)
PL (1) PL2696889T3 (es)
PT (1) PT2696889T (es)
RS (1) RS56639B1 (es)
SG (1) SG193483A1 (es)
SI (1) SI2696889T1 (es)
TW (1) TWI583698B (es)
UA (1) UA112981C2 (es)
WO (1) WO2012141936A1 (es)
ZA (1) ZA201306556B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013885A (es) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
EP4076499A4 (en) * 2019-12-19 2023-11-01 Transfert Plus Societe en Commandite USE OF GLIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF) FOR THE TREATMENT OF ENTERIC NEUROPATHIES
IL309027A (en) 2021-06-03 2024-02-01 Fundac?O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Neuro-messenger units that control ILC2 and obesity in brain fat cell circuit findings

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
NZ594481A (en) * 2009-02-06 2012-09-28 Pepscan Systems Bv Truncated cystine-knot proteins

Also Published As

Publication number Publication date
KR101554799B1 (ko) 2015-09-21
LT2696889T (lt) 2018-02-12
CA2833158C (en) 2018-07-17
RS56639B1 (sr) 2018-03-30
BR112013026004B1 (pt) 2020-09-29
PL2696889T3 (pl) 2018-04-30
SI2696889T1 (en) 2018-01-31
KR20130131470A (ko) 2013-12-03
UA112981C2 (uk) 2016-11-25
HUE036239T2 (hu) 2018-06-28
CN103635201A (zh) 2014-03-12
EA201370204A1 (ru) 2014-02-28
WO2012141936A1 (en) 2012-10-18
JP6093345B2 (ja) 2017-03-08
US20130324474A1 (en) 2013-12-05
CA2833158A1 (en) 2012-10-18
IL228102A0 (en) 2013-09-30
ES2656020T3 (es) 2018-02-22
CN103635201B (zh) 2016-11-09
EP2696889A1 (en) 2014-02-19
AU2012243178B2 (en) 2016-09-29
JP2014512369A (ja) 2014-05-22
ME02849B (me) 2018-01-20
NO2696889T3 (es) 2018-04-14
IL228102A (en) 2017-04-30
DK2696889T3 (en) 2018-01-22
US9243046B2 (en) 2016-01-26
EA025129B1 (ru) 2016-11-30
TW201245220A (en) 2012-11-16
SG193483A1 (en) 2013-10-30
CY1119750T1 (el) 2018-06-27
EP2696889B1 (en) 2017-11-15
MX2013011919A (es) 2014-03-27
BR112013026004A2 (pt) 2016-11-29
TWI583698B (zh) 2017-05-21
AU2012243178A1 (en) 2013-09-05
ZA201306556B (en) 2015-03-25
NZ614325A (en) 2015-07-31
PT2696889T (pt) 2018-02-05
HRP20171993T1 (hr) 2018-02-09

Similar Documents

Publication Publication Date Title
WO2013151736A3 (en) In vivo production of proteins
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2022000026A (es) Anticuerpos para tau.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
IL229830B (en) Novel compinds as modulatord of gpr-119
EP2767144A4 (en) METHOD, DEVICE AND PRODUCTION TO CALIBRATE LIGHTING UNITS
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
EP2808318A4 (en) CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF
EP2803657A4 (en) CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF
HUE038664T2 (hu) Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
IN2014DN11201A (es)
EP2663576A4 (en) NEW WNT COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF SUCH COMPOSITIONS
IN2014DN09450A (es)
IL234606B (en) Innovative methods and compounds for the treatment of diseases
GEP20197052B (en) Hyr1-derived compositions and methods of treatment using same
EP3027049A4 (en) Treatment of beverages to reduce the effects of noxious constituents
PT2917179T (pt) Método para a produção de ácido peracético em equilíbrio e ácido peracético em equilíbrio obtido por este método
EP2841447A4 (en) A NEW COMPOSITION FOR EXTRACORPORAL REDUCTION OF BETA AMYLOIDS AND METHOD FOR THE PRODUCTION THEREOF
MX347541B (es) Analogos de acido sialico.
MX2013011919A (es) Variantes de factor neurotrófico derivado de celulas gliales humanas.
IL231490A0 (en) Preparations and methods for the production and use of human cholinesterases
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.

Legal Events

Date Code Title Description
FG Grant or registration